FATE FATE THERAPEUTICS INC
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1434316 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-33.4%
TTM net income YoY20.3%
TTM EPS YoY22.6%
Revenue 3-yr CAGR-64.5%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-2,760.0%
Net margin-2,619.6%
FCF margin-2,249.4%
EBITDA margin-2,519.2%
Returns
ROE-67.8%
ROA-42.8%
ROIC (approx.)-73.3%
Asset turnover0.02x
Leverage & solvency
Liabilities / assets44.2%
Debt / equity0.00x
Current ratio4.41x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.85x
Accruals ratio-6.6%
Payout ratio—
Capex / revenue31.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $6.65M | $13.63M |
| R&D expense | $107.83M | $135.00M |
| SG&A expense | $46.52M | $74.17M |
| Operating income | -$147.70M | -$210.28M |
| Income tax | $2,000 | $0 |
| Net income | -$136.31M | -$186.26M |
| EBITDA | -$134.80M | -$191.31M |
| EPS (basic) | -1.15 | -1.64 |
| EPS (diluted) | -1.15 | -1.64 |
| Weighted avg. shares (diluted) | 118.79M | 113.69M |
| Balance sheet | ||
| Cash & equivalents | $46.63M | $36.06M |
| Short-term investments | $157.03M | $243.01M |
| Receivables | $916,000 | $3.54M |
| Current assets | $208.70M | $291.91M |
| PP&E, net | $56.92M | $64.38M |
| Total assets | $318.94M | $440.69M |
| Current liabilities | $36.07M | $38.52M |
| Total liabilities | $111.75M | $121.97M |
| Shareholders' equity | $207.18M | $318.73M |
| Shares outstanding | 115.36M | 113.93M |
| Cash flow statement | ||
| Operating cash flow | -$106.08M | -$122.87M |
| Capital expenditure | $5.95M | $730,000 |
| Free cash flow | -$112.04M | -$123.60M |
| Investing cash flow | $111.17M | $12.22M |
| Financing cash flow | $5.49M | $99.89M |
| Depreciation & amortization | $12.90M | $18.96M |
| Stock-based compensation | $24.92M | $41.50M |
Free plan shows the latest 2 periods; Pro shows all 18 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.